NcXHF

MAWRIN, CHUNG, AND PREUSSER
Disclosures of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: Christian Mawrin, Merck Germany (I). Honoraria: Matthias Preusser,
GSK, Roche. Christian Mawrin, Bayer Schering Pharma. Consulting or Advisory Role: None. Speakers’ Bureau: None. Research Funding: Matthias Preusser,
Böhringer Ingelheim (Inst), GSK (Inst), Roche (Inst). Caroline Chung, Pfizer. Christian Mawrin, Bayer Schering Pharma. Patents, Royalties, or Other
Intellectual Property: None. Expert Testimony: None. Travel, Accommodations, Expenses: Matthias Preusser, GSK, Roche. Other Relationships:
Christian Mawrin, Bayer Schering Pharma, Medac.
References
1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report:
primary brain and central nervous system tumors diagnosed in the
United States in 2006-2010. Neuro Oncol. 2013;15 (suppl 2):ii1-56.
2. Klaeboe L, Lonn S, Scheie D, et al. Incidence of intracranial meningiomas
in Denmark, Finland, Norway and Sweden, 1968-1997. Int J
Cancer. 2005;117:996-1001.
3. Sadetzki S, Flint-Richter P, Ben-Tal T. Radiation induced meningioma:
a descriptive study of 253 cases. J Neurosurg. 2002;97:1078-1082.
4. Schneider B, Pülhorn H, Röhrig B, et al. Predisposing conditions and
risk factors for development of symptomatic meningioma in adults.
Cancer Detect Prev. 2005;29:440-447.
5. Flint-Richter P, Mandelzweig L, Oberman B, et al. Possible interaction
between ionizing radiation, smoking, and gender in the causation of
meningioma. Neuro Oncol. 2011;13:345-352.
6. Benson VS, Pirie K, Schüz J, et al. Mobile phone use and risk of brain
neoplasms and other cancers: prospective study. Int J Epidemiol. 2013;
42:792-802.
7. Antinheimo J, Sankila R, Carpén O, et al. Population-based analysis of
sporadic and type 2 neurofıbromatosis-associated meningiomas and
schwannomas. Neurology. 2000;54:71-76.
8. Smith MJ, Higgs JE, Bowers NL, et al. Cranial meningiomas in 411
neurofıbromatosis type 2 (NF2) patients with proven gene mutations:
clear positional effect of mutations, but absence of female severity effect
on age at onset. J Med Genet. 2011;48:261-265.
9. Catala M. Embryonic and fetal development of structures associated
with the cerebro-spinal fluid in man and other species. Part I. The ventricular
system, meninges and choroid plexuses. Arch Anat Cytol
Pathol. 1998;46:153-169.
10. Mawrin C, Perry A. Pathological classifıcation and molecular genetics
of meningiomas. J Neurooncol. 2010;99:379-391.
11. Kros J, de Greve K, van Tilborg A, et al. NF2 status of meningiomas is
associated with tumour localization and histology. J Pathol. 2001;194:
367-372.
12. Lee JH, Sade B, Choi E, et al. Meningothelioma as the predominant
histological subtype of midline skull base and spinal meningioma.
J Neurosurg. 2006;105:60-64.
13. Ketter R, Rahnenführer J, Henn W, et al. Correspondence of tumor
localization with tumor recurrence and cytogenetic progression in meningiomas.
Neurosurgery. 2008;62:61-69.
14. Pearson BE, Markert JM, Fisher WS, et al. Hitting a moving target:
evolution of a treatment paradigm for atypical meningiomas amid
changing diagnostic criteria. Neurosurg Focus. 2008;24:E3.
15. Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas:
a study of prognostic factors. J Neurooncol. 2009;95:367-375.
16. Perry A, Scheithauer BW, Stafford SL, et al. “Malignancy” in meningiomas:
a clinicopathologic study of 116 patients, with grading implications.
Cancer. 1999;85:2046-2056.
17. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an
analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455-
1465.
18. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene
encoding a putative membrane-organizing protein causes neurofıbromatosis
type 2. Nature. 1993;363:515-521.
19. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-,
radixin-like gene is a candidate for the neurofıbromatosis 2 tumor suppressor.
Cell. 1993;72:791-800.
20. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofıbromatosis
in the United Kingdom. I. Prevalence, mutation rate,
fıtness, and confırmation of maternal transmission effect on severity.
J Med Genet. 1992;29:841-846.
21. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular
genetic approach to human meningioma: loss of genes on chromosome
22. Proc Natl Acad SciUSA.1987;84:5419-5423.
22. Dumanski JP, Carlbom E, Collins VP, et al. Deletion mapping of a locus
on human chromosome 22 involved in the oncogenesis of meningioma.
Proc Natl Acad SciUSA.1987;84:9275-9279.
23. Ruttledge MH, Xie YG, Han FY, et al. Deletions on chromosome 22 in
sporadic meningioma. Genes Chromosomes Cancer. 1994;10:122-130.
24. Dumanski JP, Rouleau GA, Nordenskjold M, et al. Molecular genetic
analysis of chromosome 22 in 81 cases of meningioma. Cancer Res.
1990;50:5863-5867.
25. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete
inactivation of the NF2 gene in the majority of sporadic meningiomas.
Nat Genet. 1994;6:180-184.
26. Gutmann DH, Giordano MJ, Fishback AS, et al. Loss of merlin expression
in sporadic meningiomas, ependymomas and schwannomas.
Neurology. 1997;49:267-270.
27. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signaling
and intercellular contact. Br J Cancer. 2008;98:256-262.
28. Wellenreuther R, Kraus JA, Lenartz D, et al. Analysis of the neurofıbromatosis
2 gene reveals molecular variants of meningioma. Am J
Pathol. 1995;146:827-832.
29. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing
of meningiomas identifıes oncogenic SMO and AKT1 mutations. Nat
Genet. 2013;45:285-289.
30. Goutagny S, Yang HW, Zucman-Rossi J, et al. Genomic profıling reveals
alternative genetic pathways of meningioma malignant progression
dependent on the underlying NF2 status. Clin Cancer Res. 2010;
16:4155-4164.
31. Hartmann C, Sieberns J, Gehlhaar C, et al. NF2 mutations in secretory
and other rare variants of meningiomas. Brain Pathol. 2006;16:15-19.
e112
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook